A few structural errors are noticed and listed as follows. A double bond was omitted in the original structure of imidazopyridine-1, TBA-7371, and Q203 in [Figures [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}, respectively. The stereochemistry was not illustrated in the original structure of GSK-070 in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}. The full structure of OPC-167832 was not demonstrated in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}. All these errors have been corrected as shown below.

![Hit compounds (A) identified in target-based whole-cell screens and (B) identified in whole-cell screen under growth culture conditions and discussed in the text. Also see Table 2.](cr-2019-00244c_0001){#fig4}

![Hit compounds identified in intracellular whole-cell screens against Mtb-infected macrophages and discussed in the text. Also see Table 2.](cr-2019-00244c_0002){#fig7}

![TB compounds identified in the screens outlined in Table 2 that are currently in clinical trials.](cr-2019-00244c_0003){#fig8}
